recipient families, including those also receiving Food Stamps. Would not apply to initial eligibility determination.

Date Received: 10/3/95.

Type: AFDC.

Current Status: Pending.

Contact Person: Bill Biggs, (801) 538–4337.

III. Listing of Approved Proposals Since December 1, 1995

Project Title: California—School Attendance Demonstration Project.

Contact Person: Bruce Wagstaff, (916) 657–2367.

Project Title: Connecticut—Reach for Jobs First (a modification of previously approved Fair Chance Demonstration).

Contact Person: Nancy Wiggett, (203) 424–5329.

IV. Requests for Copies of a Proposal

Requests for copies of an AFDC or combined AFDC/Medicaid proposal should be directed to the Administration for Children and Families (ACF) at the address listed above. Questions concerning the content of a proposal should be directed to the State contact listed for the proposal.

(Catalog of Federal Domestic Assistance Program, No. 93562; Assistance Payments—Research)

Dated: February 7, 1996.

Karl Koerper,

Director, Division of Economic Independence, Office of Planning, Research and Evaluation.

[FR Doc. 96–3300 Filed 2–13–96; 8:45 am]

BILLING CODE 4184–01–P

Centers for Disease Control and Prevention

CDC WONDER Information Systems

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services.

ACTION: Notice of availability.

SUMMARY: This notice announces the availability of three CDC WONDER information systems, effective February 15, 1996. This notice is in compliance with OMB Circular A–130 Transmittal 2, Management of Federal Information Resources to provide adequate notice when initiating, substantially modifying, or terminating significant information dissemination products.

EFFECTIVE DATE: February 15, 1996.

FOR FURTHER INFORMATION CONTACT: Dianne Wylie, Assistant Chief, Public Health Information Systems Branch, Information Resources Management Office, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, NE., Mailstop F–51, Atlanta, Georgia 30341–3724, telephone (770) 488–7510.

SUPPLEMENTARY INFORMATION: (1) ''CDC WONDER for the PC'' is a microcomputer-based information and communications system that provides menu-driven access to more than 25 public health databases, including data on mortality, morbidity, hospitalizations, and documents on CDC health policies. A microcomputer and modem are required. Software and manuals may be ordered from USD, 2075 A West Park Place, Stone Mountain, Georgia 30087, telephone (770) 469–4098, fax (770) 469–0681. To order product literature and registration forms telephone (770) 469–0503. The full package WONDER User ID, software, and manual costs $50.00 (product number: USDCDCWS); documentation only is $25.00 (product number: USDCDCMO); a user account (ID and Password) only is $23.00 (product number: USDCDCUA); diskettes only are $10.00 (product number: USDCDCDO). The training video ''Cafe WONDER'' costs $19.95 (product number: USDCDCV).

Employees of State and local health departments may obtain User ID's only free of charge. State/local health department employees should mail a completed CDC WONDER user registration form along with a letter on official health department stationery to CDC WONDER User Support, 4770 Buford Highway, Mailstop F–51, Atlanta, Georgia 30341. The letter should state that, as an employee of the health department, individuals are requesting that CDC provide a CDC WONDER User ID at no charge. Note: (1) faxed letters cannot be accepted; and (2) no software will accompany these User IDs. Health department staff who receive a User ID in this way will need to acquire a copy of the WONDER software and documentation from a colleague, or by purchasing them from USD.

(2) ''CDC WONDER on the Web'' is an Internet information system that provides menu-driven access to more than 25 public health databases, including data on mortality, morbidity, hospitalizations, and documents on CDC health policies. It may be accessed at http://wonder.cdc.gov. A Web browser and access to the Internet is required. There are no user fees.

(3) ''The CDC Prevention Guidelines on CD–ROM'' is a compact disk that provides rapid access to one of the databases in CDC WONDER on the Web. This database contains more than 400 documents containing authoritative recommendations from CDC on a wide variety of public health topics. The documents range in length from a few pages to several hundred. The CD may be ordered for $49.95 from USD, 2075 A West Park Place, Stone Mountain, Georgia 30087, telephone (770) 469–4098; fax (770) 469–0681.

Dated: February 8, 1996.

Joseph R. Carter,

Acting Associate Director for Management and Operations Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–3260 Filed 2–13–96; 8:45 am]

BILLING CODE 4163–18–P

Clinical Laboratory Improvement Advisory Committee (CLIAC), Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting:

Name: Clinical Laboratory Improvement Advisory Committee.

Times and Dates: 2–5 p.m., March 5, 1996; 8 a.m.–4:30 p.m., March 6, 1996.

Place: CDC, Auditorium B, Building 2, 1600 Clifton Road, NE, Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available.

Purpose: This committee is charged with providing scientific and technical advice and guidance to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the need for, and the nature of, revisions to the standards under which clinical laboratories are regulated; the impact of proposed revisions to the standards; and the modification of the standards to accommodate technological advances.

Matters To Be Discussed: The agenda will include an orientation for new members regarding the roles and responsibilities of an advisory committee member; a CDC update on the status of the publication of proposed rules for cytology, Accurate and Precise Technology, and waiver; a Health Care Financing Administration update on implementation of the Clinical Laboratory Improvement Amendments; a Federal Drug Administration update; and presentations on the use of automated cytology instruments.

Demonstrations will be provided of computer-based cytology proficiency testing (PT) developed in cooperative agreement with CDC. A major impediment in making cytology PT available on a national basis has been and continues to be the difficulty in obtaining a sufficient number of properly referenced glass slides. Computer-based programs offer the advantage of providing for the accumulation and assembly of sufficient numbers of well-documented, referenced cytology preparations that can be used for testing individuals in a consistent and uniform manner. In December 1993, the CLIAC recommended that studies be conducted to evaluate the effectiveness of

both glass slide PT programs and programs employing alternative media, including computer-based PT programs.

CLIAC solicits oral and written testimony on the use of computer-based cytology PT programs. Requests to make an oral presentation should be submitted in writing to the contact person listed below by close of business, March 1, 1996. Written comments should not exceed five single-spaced, typed pages in length and should be received by the contact person listed below by close of business, February 29, 1996.

Agenda items are subject to change as priorities dictate.

For Further Information Contact:
John C. Ridderhof, Dr. P.H., Division of Laboratory Systems, Public Health Practice Program Office, CDC, 4770 Buford Highway, NE., Mailstop G–25, Atlanta, Georgia 30341–3724, telephone (770) 488–7660, Fax (770) 488–7663.

Dated: February 8, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office Centers for Disease Control and Prevention.

[FR Doc. 96–3244 Filed 2–13–96; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

[Docket No. 91N–0428]

Briefing Document for Biological Response Modifiers Advisory Committee; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a draft document entitled ''Addendum to the Points to Consider on Human Somatic Cell and Gene Therapy (1991).'' This draft addendum is being made available as briefing material for the February 1996 Biological Response Modifiers Advisory Committee meeting. This action is being taken to ensure that all interested parties are aware of the information in the document that will be the subject of the committee's discussion.

DATES: Written comments by March 28, 1996.

ADDRESSES: Submit written requests for single copies of the draft Points to Consider (PTC) addendum to the Division of Congressional and Public Affairs (HFM–11), Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448. Send one self-addressed adhesive label to assist that office in processing your requests. The document may also be obtained by mail, or FAX by calling the CBER Voice Information System at 1–800–835–4709.

Persons with access to the INTERNET may obtain the document in several ways. Users of ''Web Browser'' software, such as Mosaic, Netscape, or Microsoft Internet Explorer may obtain this document via the World Wide Web by using the following Uniform Resource Locators:

http://www.fda.gov/cber/cberftp.html
ftp://ftp.fda.gov/CBER/

The document may also be obtained via File Transfer Protocol (FTP). Requesters should connect to FDA's FTP Server, FTP.FDA.GOV (192.73.61.21). CBER documents are maintained in a subdirectory called ''CBER'' on the server. Logins with the user name of anonymous are permitted, and the user's e-mail address should be sent as the password. The ''READ.ME'' file in that subdirectory describes the available documents which may be available as an ASCII text file (*.TXT), or a WordPerfect 5.1 or 6.x document (*.w51,wp6), or both. Finally, the document can be obtained by ''bounce-back e-mail''. A message should be sent to: ''GTSA@A1.CBER.FDA.GOV''.

Submit written comments on the draft PTC addendum to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857. Two copies of any comments are to be submitted, except that individuals may submit one copy. Requests and comments should be identified with the docket number found in brackets in the heading of this document. A copy of the draft PTC addendum and received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

FOR FURTHER INFORMATION CONTACT: Suzanne L. Epstein, Center for Biologics Evaluation and Research (HFM–521), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–827–0450.

SUPPLEMENTARY INFORMATION: FDA is announcing the availability of briefing material being supplied to the advisory committee as background information for the meeting. The draft PTC addendum is being made available as briefing material prior to the advisory committee meeting to ensure that all interested parties have an opportunity to obtain and review the material in advance of the meeting. A notice announcing the February 1996 Biological Response Modifiers Advisory Committee meeting and agenda was published in the Federal Register of January 31, 1996 (61 FR 3427 at 3428).

In the Federal Register of November 29, 1991 (56 FR 61022), FDA announced the availability of a draft PTC document entitled ''Points To Consider in Human Somatic Cell Therapy and Gene Therapy.'' At that time, most gene therapy proposals involved ex vivo use of retroviral vectors to transduce cultured cells, which were then administered to patients. Since that time, the range of proposals has expanded to include additional classes of vectors and also the in vivo use of vectors (direct vector administration to patients). Accordingly, FDA has drafted an addendum to the 1991 PTC in Human Somatic Cell and Gene Therapy that includes current information regarding the production, testing, and administration of recombinant vectors for gene therapy. Prior to making a draft PTC addendum available for industry use, FDA is presenting the issues discussed in the document at the next advisory committee meeting.

As with other PTC documents, FDA does not intend the draft PTC addendum to be all-inclusive and cautions that not all information may be applicable to all situations. The draft PTC addendum is intended to provide information and does not set forth requirements. FDA anticipates that manufacturers and other interested parties may develop alternative methods and procedures, and discuss them with FDA. FDA recognizes that advances will continue in the area of somatic cell and gene therapy, and FDA intends to update and revise the document in order to improve its usefulness. The draft PTC addendum does not bind FDA and does not create or confer any rights, privileges, or benefits on or for any person, but is intended merely for guidance.

Comments received from the meeting and comments submitted to the Dockets Management Branch will be considered in determining whether revision of the draft PTC addendum is warranted. At a later date after the meeting, a Federal Register notice will be published to announce the availability of the PTC addendum for industry use. The PTC addendum will provide CBER's current thinking regarding issues related to gene therapy.

The briefing document and received comments may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday.